Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Female
Advanced Breast Cancer
Female
Advanced Breast Cancer
Trial Information
Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.
Inclusion Criteria:
- HER2-positive breast cancer Trastuzumab-containing regimen delivered for advanced
disease Tumor sample available at Pathology Archive
Exclusion Criteria:
- HER2-negative advanced breast cancer Pretreatment with trastuzumab
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Association of tumor cytogenetic paremeters with TTP and OS.
Outcome Time Frame:
one year
Safety Issue:
No
Principal Investigator
Armando Santoro, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ONC/OSS-03-2008
NCT ID:
NCT00874146
Start Date:
March 2009
Completion Date:
December 2009
Related Keywords:
- Advanced Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
